bupropion/naltrexone (Contrave)

^[1]^[2]^[3]^[4]

Introduction

FDA approved for treatment of obesity Sept 2014^[2]

clinical trial safety testing halted due to unauthorized release of data compromising study's integrity^[3]
cardiovascular risks still unknown^[4]

↑ Physician's First Watch, Dec 8, 2010 Massachusetts Medical Society http://www.jwatch.org
Astrup A. Is cardiometabolic risk improved by weight-loss drugs? Lancet 2010 Aug 21; 376:567 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20673996
↑ ^2.0 ^2.1 Nainggolan L FDA Approves Bupropion/Naltrexone (Contrave) for Obesity. Medscape: Sppt 10, 2014 http://www.medscape.com/viewarticle/831513
FDA News Release. September 10, 2014 FDA approves weight-management drug Contrave. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm413896.htm
↑ ^3.0 ^3.1 Cleveland Clinic News Release. May 12, 2015 Clinical Trial Testing Safety Of Obesity Drug Contrave Halted; 50 Percent Interim Data Released By The Study's Executive Committee. http://my.clevelandclinic.org/about-cleveland-clinic/newsroom/releases-videos-newsletters/2015-5-12-clinical-trial-testing-safety-of-obesity-drug-contrave-halted
↑ ^4.0 ^4.1 Nissen SE, Wolski KE, Prcela L et al Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016 Mar 8;315(10):990-1004. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26954408
Sharfstein JM, Psaty BM. Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted. JAMA. 2016 Mar 8;315(10):984-6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26954405